At variance, GSK3A, but not GSK3B, has been identified as a therapeutic target in melanoma [15] suggesting that, similarly to what has been reported for normal cells, the two isoforms can play both distinct or redundant roles depending on the cancer cell type. This evidence concerns the gene GSK3B and melanoma.